在广泛阶段的SCLC中实现长期生存:一个病例报告和迷你文献综述
Yayun Mao1, Meiping Huang1, Jiafu Liu1
1Fuzhou Pulmonary Hospital of Fujian, Clinical Teaching Hospital of Fujian Medical University, Fuzhou, Fujian, 350008, China.
Lung cancer management
|May 31, 2024
概括
这项扩展阶段小细胞肺癌 (SCLC) 病例研究显示,一个患者在积极治疗下存活了六年. 它强调了个性化策略,以改善SCLC患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
背景情况:
- 扩散阶段小细胞肺癌 (ES-SCLC) 由于其侵略性和患者预后不佳,提出了重大临床挑战.
- 目前的管理策略往往给ES-SCLC患者带来有限的长期存活率.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.6K
相关概念视频
Cancer Survival Analysis
343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
